Abstract
Purpose: :
To evaluate the use of intravitreal ketorolac as an alternative to steroids in the treatment of macular edema.
Methods: :
Retrospective non–randomized case series. Inclusion criteria were a previous steroid response or diagnosis of glaucoma and no previous eye surgery within 3 months of intravitreal ketorolac injection and macular edema. Fluorescein angiography and optical coherence tomography were performed at baseline, 1 week, 1 month and 3 months. ETDRS visual acuity was performed at the same intervals.
Results: :
Total of 7 eyes were reviewed with the following diagnosis: diabetic macular edema (4 eyes), chronic cystoid macular edema (2 eyes) and central retinal vein occlusion (CRVO) with macular edema ( 1 eye). Intravitreal ketorolac dosis was 60 mcg–90 mcg/0.1 ml in diabetic eyes, 200 mcg/0.1 ml in CME eyes and 900 mcg/0.1 ml in CRVO eye. Visual acuity improvement of 2 lines or more were seen in 2 diabetic eyes and 1 eye with CRVO and macular edema. The remainder of the eyes were stable. Complications such as cataract and increased intraocular pressure were not seen.
Conclusions: :
Intravitreal ketorolac may be considered as an alternative to steroids in selected patients. In this small pilot study no complications were observed.
Keywords: macula/fovea • diabetic retinopathy • drug toxicity/drug effects